Status:
COMPLETED
Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
Lead Sponsor:
Hartford Hospital
Conditions:
Specific Phobia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and ...
Detailed Description
D-cycloserine (DCS) is a partial N-methyl-D-aspartate (NMDA) receptor agonist that may improve or accelerate extinction learning. We will randomly assign people with snake phobia to receive DCS or pla...
Eligibility Criteria
Inclusion
- Primary diagnosis of specific phobia (snakes)
Exclusion
- History of psychosis, obsessive-compulsive disorder, or mania
- Recent substance abuse or suicidality
- Previous receipt of study treatments
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01450306
Start Date
July 1 2010
End Date
December 1 2011
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Living/Hartford Hospital
Hartford, Connecticut, United States, 06106